EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of IFITM3 in cerebrovascular endothelium alleviates Alzheimer's‐related phenotypes

Yijia Feng, Shengya Wang, Danlu Yang, Wu Zheng, Huwei Xia, Qinxin Zhu, Zhipeng Wang, Bolang Hu, Xinyi Jiang, Xuemei Qin, Chenkang Ni, Wenhao Pan und 4 weitere

Alzheimer's & Dementia · 2025-02 · 21 (2)

DOI: 10.1002/alz.14543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 14.01.2025. Verfasst von Yijia Feng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Geriatric Medicine, Key Laboratory of Alzheimer's Disease of Zhejiang Province, The First Affiliated Hospital and Institute of Aging, Wenz…. Hauptthemen laut MEDLINE: Alzheimer Disease, Membrane Proteins, RNA-Binding Proteins, Endothelial Cells. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Interferon‐induced transmembrane protein 3 (IFITM3) modulates γ‐secretase in Alzheimer's Disease (AD). Although IFITM3 knockout reduces amyloid β protein (Aβ) production, its cell‐specific effect on AD remains unclear. METHODS Single nucleus RNA sequencing (snRNA‐seq) was used to assess IFITM3 expression. Adeno‐associated virus‐BI30 (AAV‐BI30) was injected to reduce IFITM3 expression in the cerebrovascular endothelial cells (CVECs). The effects on AD phenotypes in cells and AD mice were examined through behavioral tests, two‐photon imaging, flow cytometry, Western blot, immunohistochemistry, and quantitative polymerase chain reaction assay (qPCR). RESULTS IFITM3 expression was increased in the CVECs of patients with AD. Overexpression of IFITM3 in primary endothelial cells enhanced Aβ generation through regulating beta‐site APP cleaving enzyme 1 (BACE1) and γ‐secretase. Aβ further increased IFITM3 expression, creating a vicious cycle. Knockdown of IFITM3 in CVECs decreased Aβ accumulation within cerebrovascular walls, reduced Alzheimer's‐related pathology, and improved cognitive performance in AD transgenic mice. DISCUSSION Knockdown of IFITM3 in CVECs alleviates AD pathology and cognitive impairment. Targeting cerebrovascular endothelial IFITM3 holds promise for AD treatment. Highlights Interferon‐induced transmembrane protein 3 ( IFITM3 ) expression was increased in the cerebrovascular endothelial cells (CVECs) of patients with Alzheimer's Disease (AD). Cerebrovascular endothelial IFITM3 regulates amyloid β protein (Aβ) generation through regulating beta‐site APP cleaving enzyme 1 (BACE1) and γ‐secretase. Knockdown of IFITM3 in CVECs reduces Aβ deposits and improves cognitive impairments in AD transgenic mice. Cerebrovascular endothelial IFITM3 could be a potential target for the treatment of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMembrane ProteinsRNA-Binding ProteinsEndothelial CellsEndothelium, VascularAnimalsMiceHumansAmyloid Precursor Protein SecretasesAmyloid beta-PeptidesPhenotypeAspartic Acid EndopeptidasesMice, TransgenicDisease Models, AnimalMale

Stichwörter der Autor:innen

Alzheimer's DiseaseAβIFITM3cerebrovascular endotheliumcognitive impairment

Substanzen

Membrane ProteinsRNA-Binding ProteinsIFITM3 protein, humanAmyloid Precursor Protein SecretasesAmyloid beta-PeptidesAspartic Acid Endopeptidases

Autor:innen und Institutionen

  • Center for Geriatric Medicine, Key Laboratory of Alzheimer's Disease of Zhejiang Province, The First Affiliated Hospital and Institute of Aging, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Neuroscience Medical Center, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China.
  • Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, China.
  • Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Feng, Y., Wang, S., Yang, D., Zheng, W., Xia, H., Zhu, Q., Wang, Z., Hu, B., Jiang, X., Qin, X., Ni, C., Pan, W., Zhao, Y., Pan, S., Zhang, Y., & Song, W. (2025). Inhibition of IFITM3 in cerebrovascular endothelium alleviates Alzheimer's‐related phenotypes. Alzheimer's & Dementia, 21(2). https://doi.org/10.1002/alz.14543

Vancouver

Feng Y, Wang S, Yang D, Zheng W, Xia H, Zhu Q, et al. Inhibition of IFITM3 in cerebrovascular endothelium alleviates Alzheimer's‐related phenotypes. Alzheimer's & Dementia. 2025;21(2). doi:10.1002/alz.14543

BibTeX
@article{Feng2025,
  author = {Feng, Yijia and Wang, Shengya and Yang, Danlu and Zheng, Wu and Xia, Huwei and Zhu, Qinxin and Wang, Zhipeng and Hu, Bolang and Jiang, Xinyi and Qin, Xuemei and Ni, Chenkang and Pan, Wenhao and Zhao, Yifan and Pan, Sipei and Zhang, Yun and Song, Weihong},
  title = {Inhibition of IFITM3 in cerebrovascular endothelium alleviates Alzheimer's‐related phenotypes},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {2},
  doi = {10.1002/alz.14543}
}
Kostenlos starten →